Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 591 - 600 of 785 studies

Predicting Long-Term Success and Identifying Optimal Treatment Strategies for Idiopathic Toe Walking

Clinical Management and Short-Term Outcomes of Neonates Born at 22 Weeks in UK Neonatal Intensive Care Units

Cancer and neoplasms

NX-5948-201 - A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Inflammatory and immune system

A phase 2a and 2b randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pacritinib in patients with VEXAS syndrome (PAXIS)

Cancer and neoplasms

BCA101X301 - A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1- positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BCA101X301)

Cancer and neoplasms

IAM1363-01 - A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations

Cancer and neoplasms

An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors (CECI830A12101)

Oral and Gastrointestinal

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide. (ACT18053)

Cancer and neoplasms Metabolic and Endocrine

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumor (CAREFNDR (CRN00808-12))

Respiratory

A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients with Idiopathic Pulmonary Fibrosis. (CAL101-201 (AURORA))